NCT04169672View on ClinicalTrials.gov

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

PHASE2CompletedINTERVENTIONAL

Enrollment

248

Participants

Timeline

Start Date

December 26, 2019

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions

Advanced Solid Tumors

Interventions

DRUG

Surufatinib

Surufatinib is a tablet in the form of 50mg, oral, once a day.

DRUG

Toripalimab

Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

Trial Locations (2)

100142

Beijing Cancer Hospital, Beijing

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Hutchison Medipharma Limited

INDUSTRY

NCT04169672 - Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter